Browse by Series:

FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More

Gina Columbus
Published: Friday, Dec 23, 2016



Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
Slider Left
Slider Right


Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x